|
|
|
|
|
By Rishi Ramesh Kothari, gene therapy CMC expert
|
Biologics tech transfer means sharing up to 20 assays. Miss a step, and you risk delays, bad data, and products stuck in limbo.
|
|
|
|
|
How This CDMO Model Is Empowering Emerging Biotechs
|
Article | Cytovance Biologics
|
For emerging biotechs looking to refine their development processes and boost their chances of commercial success, exploring these partnership opportunities could prove invaluable.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Single-use systems (SUS) are everywhere—but standardization hasn’t caught up. Join Bioprocess Online Live for a timely discussion on how the lack of SUS standards is impacting implementation, tech transfer, and supply chain stability—and what the industry must do next. Registration is free thanks to the support of CPC.
|
|
|
Connect With Bioprocess Online: |
|
|
|